|
1) Winthrop KL. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view. Future Microbiol. 2010; 5: 343-5
|
|
|
|
2) O'Brien RJ, Geither LJ, Snider DE Jr. The epidemiology nontuberculous mycobacterial disease in the United States; results from a national survey. Am Rev Respir Dis. 1987; 135: 1007-14
|
|
|
|
|
|
3) Marras TK, Chedore P, Ying AM, et al. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax. 2007; 62: 661-6
|
|
|
|
|
|
4) Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am Resp Crit Care Med. 2007; 175: 367-416
|
|
|
|
|
|
5) Cassidy MP, Hedberg K, Saulson A, et al. Nontuberculous mycobacterial disease prevalence and risk factors; a changing epidemiology. Clin Infect Dis. 2009; 49: E124-9
|
|
|
|
|
|
6) Billinger ME, Olivier KN, Viboud C, et al. Nontuberculous mycobacteria-associated lung disease in hospitalized person, United States, 1998-2005. Emerg Infect Dis. 2009; 15: 1562-9
|
|
|
|
|
|
7) Bodle EE, Cunningham JA, Della-Latta P, et al. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerging Infectious Diseases. 2008; 14: 390-6
|
|
|
|
|
|
8) Henry MT, Inamdar L, O'Riordain D, et al. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J. 2004; 23: 741-6
|
|
|
|
|
|
9) Maugein J, Dailloux M, Carbonnelle B, et al. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur Respir J. 2005; 26: 1092-6
|
|
|
|
|
|
10) Ingen JV, Bendien SA, de Lange WCM, et al. Clinical relevance of non-tuberculous mycobacteria isolated in Nijimen-Arnhem region, The Netherlands. Thorax. 2009; 64: 502-6
|
|
|
|
|
|
11) Andréjak C, Thomsen VØ, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010; 5: 514-21
|
|
|
|
|
|
12) Lai CC, Tan CK, Chou CH, et al. Increasing Incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerging Infectious Diseases. 2010; 16: 294-6
|
|
|
|
|
|
13) 高橋光良. 結核とM. avium感染症の分子疫学. 資料と展望. 2004; 51: 57-70
|
|
|
|
|
|
14) 西森 敬, 内田郁夫, 田中 聖, 他. VNTR (Vriable Numbers of Tandem Repeats )型別による結核菌群及び鳥型結核菌の分子疫学的解析マニュアル. 動衛研研究報告. 2003; 109: 25-32
|
|
|
|
|
|
15) 桑原克弘, 渡辺 靖, 和田光一, 他. IS1245を用いた肺Mycobacterium avium症の臨床病型と 多クローン性感染の関連についての分子疫学的検討. 結核. 2004; 79: 39-46
|
|
|
|
|
16) Ichikawa K, Yagi T, Moriyama M, et al. Characterization of Mycobacterium avium clinical isolates in Japan using subspecies-specific insertion sequence, and identification of a new insertion sequence, ISMav6. Jounal of Medical Myclobiology. 2009; 58: 945-50
|
|
|
|
|
|
17) Ehlers S. Tumor necrosis factor and its blockade in granulomaotous infections: differential modes of action of Infliximab and Etanercept？ Clinical Infectious Diseases. 2005; 41: S199-203
|
|
|
|
|
|
18) Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by Infliximab. Clinical Infectious Diseases. 2005; 41: S194-8
|
|
|
|
|
|
19) Okubo H, Iwamoto M, Yoshio T, et al. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mpd Rheumatol. 2005; 15: 62-4
|
|
|
|
|
|
20) Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-α therapy. Emerging Infectious Diseases. 2009; 15: 1556-61
|
|
|
|
|